<a href="https://laohu8.com/S/IOBT">IO Biotech</a> Announces Promising Results in Phase 3 Trial of Cylembio Plus KEYTRUDA for Advanced Melanoma, Plans FDA Meeting
IO Biotech Inc. has announced clinical improvement in progression-free survival demonstrated in a pivotal Phase 3 trial of Cylembio® combined with KEYTRUDA® (Pembrolizumab) for the treatment of first-line advanced melanoma. The results showed that patients treated with the combination therapy achieved an improvement in progression-free survival compared to those treated with pembrolizumab monotherapy, with a hazard ratio of 0.77 and a median progression-free survival of 19.4 months versus 11.0 months. However, the study's primary endpoint narrowly missed the statistical significance threshold. IO Biotech plans to discuss the data with the United States Food and Drug Administration this fall to determine next steps for submission of a Biologics License Application. The company also plans to present more detailed results from the IOB-013 study at a future medical meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IO Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-177471), on August 11, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。